Small molecule · Inhibitor of NRAS · developed by Relay Therapeutics
RLY-8161 is an orally bioavailable, NRAS-selective inhibitor that binds NRAS and inhibits its activity, suppressing NRAS-dependent signaling. It is being studied in advanced NRAS-mutant melanoma and other NRAS-mutant solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07584226 | Phase 1/2 | Advanced NRAS-Mutant Melanoma | Recruiting | RLAY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced NRAS-Mutant MelanomaAdvanced NRAS-Mutant Solid TumorsNRAS G12DNRAS G12VNRAS G13DNRAS G13RNRAS MutationNRAS Q61HNRAS Q61KNRAS Q61LNRAS Q61R
Updated Nov 1, 2026. Something wrong or missing? Report it on the RLAY page.
See RLAY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RLAY catalysts and pipeline →